Rituximab is a medication used in this study to prevent certain infections and disorders after a kidney transplant. It is given early to patients who have received a kidney from a donor with a specific virus, called EBV, to help stop the virus from causing problems. The study is looking at how well Rituximab works in stopping the virus from causing an infection or a type of disorder that can happen after a transplant.

Epstein-Barr Virus Primary Infection – This infection occurs when a person is first exposed to the Epstein-Barr virus (EBV), which is a common virus that can cause infectious mononucleosis. The virus is typically spread through bodily fluids, primarily saliva. After the initial infection, the virus remains dormant in the body and can reactivate later. Symptoms of primary infection may include fatigue, fever, sore throat, and swollen lymph nodes. In some cases, the infection can be asymptomatic, especially in children. The virus can be detected through blood tests that identify EBV DNA or antibodies.

Post-Transplant Lymphoproliferative Disorder – This disorder is a complication that can occur after an organ transplant, such as a kidney transplant, due to the immunosuppressive medications used to prevent organ rejection. It involves the abnormal growth of lymphoid cells, which can lead to the development of lymphomas. The condition is often associated with Epstein-Barr virus infection, as the virus can drive the proliferation of these cells. Symptoms may include fever, swollen lymph nodes, and organ dysfunction. The disorder can vary in severity, ranging from benign growths to aggressive lymphomas. Monitoring and early detection are crucial for managing the condition effectively.